DOCSLIB.ORG

The Activation of Α1-Adrenoceptors Is Implicated in the Antidepressant-Like Effect of Creatine in the Tail Suspension Test

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Activation of Α1-Adrenoceptors Is Implicated in the Antidepressant-Like Effect of Creatine in the Tail Suspension Test CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Progress in Neuro-Psychopharmacology & Biological Psychiatry 44 (2013) 39–50 Contents lists available at SciVerse ScienceDirect Progress in Neuro-Psychopharmacology & Biological Psychiatry journal homepage: www.elsevier.com/locate/pnp The activation of α1-adrenoceptors is implicated in the antidepressant-like effect of creatine in the tail suspension test Mauricio P. Cunha, Francis L. Pazini, Ágatha Oliveira, Luis E.B. Bettio, Julia M. Rosa, Daniele G. Machado, Ana Lúcia S. Rodrigues ⁎ Department of Biochemistry, Center of Biological Sciences, Universidade Federal de Santa Catarina, 88040-900, Florianópolis, SC, Brazil article info abstract Article history: The antidepressant-like activity of creatine in the tail suspension test (TST) was demonstrated previously by Received 5 September 2012 our group. In this study we investigated the involvement of the noradrenergic system in the Received in revised form 8 January 2013 antidepressant-like effect of creatine in the mouse TST. In the first set of experiments, creatine administered Accepted 18 January 2013 by i.c.v. route (1 μg/site) decreased the immobility time in the TST, suggesting the central effect of this com- Available online 26 January 2013 pound. The anti-immobility effect of peripheral administration of creatine (1 mg/kg, p.o.) was prevented by the pretreatment of mice with α-methyl-p-tyrosine (100 mg/kg, i.p., inhibitor of tyrosine hydroxylase), Keywords: α α Antidepressant prazosin (1 mg/kg, i.p., 1-adrenoceptor antagonist), but not by yohimbine (1 mg/kg, i.p., 2-adrenoceptor Creatine antagonist). Creatine (0.01 mg/kg, subeffective dose) in combination with subeffective doses of amitriptyline Noradrenaline (1 mg/kg, p.o., tricyclic antidepressant), imipramine (0.1 mg/kg, p.o., tricyclic antidepressant), reboxetine Tail suspension test (2 mg/kg, p.o., selective noradrenaline reuptake inhibitor) or phenylephrine (0.4 μg/site, i.c.v., α1- adrenoceptor agonist) reduced the immobility time in the TST as compared with either drug alone. These results indicate that the antidepressant-like effect of creatine is likely mediated by an activation of α1- adrenoceptor and that creatine produces synergistic effects in the TST with antidepressants that modulate noradrenaline transporter, suggesting that an improvement in the response to the antidepressant therapy may occur when creatine is combined with these antidepressants. Furthermore, the synergistic effect of cre- atine (0.01 mg/kg, p.o.) and reboxetine (2 mg/kg, p.o.) combination was abolished by the α1-adrenoceptor antagonist prazosin, indicating that the antidepressant-like effect of combined therapy is likely mediated by an activation of α1-adrenoceptor. © 2013 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction Besides the monoaminergic hypothesis, impairment in the brain energetic metabolism has been implicated in the pathophysiology of de- Depression is one of the most common illnesses characterized by a pression. Several studies have demonstrated alterations in high-energy broad range of symptoms, including altered mood and cognitive func- phosphate metabolism in subjects with depression (Kato et al., 1992; tions, loss of interest or pleasure, feelings of guilt or low self-worth, Volz et al., 1998). Indeed, a hypoactive prefrontal cerebral energy metab- disturbed sleep or appetite, low energy and recurrent thoughts of olism has been reported in unipolar and bipolar depression (Forester et death or suicide. The antidepressants used for the treatment of this al., 2009; Ketter et al., 2001). Of note, antidepressants treatment in- disorder act by increasing the availability of monoamines (serotonin, creased the energetic metabolism in the brain, since antidepressants noradrenaline and dopamine) in the synaptic cleft by blocking their treatment increased the citrate synthase activity in the mitochondrial reuptake (tricyclics, selective serotonin reuptake inhibitors, selective brain (Hroudova and Fisar, 2010), creatine kinase activity in the cerebral noradrenaline reuptake inhibitors and dopamine reuptake inhibitors) cortex (Assis et al., 2009; Réus et al., 2012; Santos et al., 2009; Scaini et al., or its metabolism (monoamine oxidase inhibitors) (Vetulani and 2010) and brain levels of creatine-containing compounds (Papakostas, Nalepa, 2000). Requisite brain regions that mediate these events are 2009; Silveri et al., 2003). Furthermore, electroconvulsive shock in- unknown, although Samson et al. (2011) reported that activation in creased the cerebral glucose utilization in the hippocampus, suggesting the prefrontal cortex seems to play a crucial role in the treatment that this intervention that is well-known to cause antidepressant effect, responses of patients with major depression. increases metabolic rates (Orzi et al., 1987). It is, therefore, feasible to suppose that agents that improve cellular bioenergetics may be useful in the treatment of depression. Abbreviations: AMPT, α-methyl-p-tyrosine; ANOVA, analysis of variance; DMSO, In line with this, creatine (N-aminoiminomethyl-N-methylglycine), a dimethylsulfoxide; FST, forced swimming test; TST, tail suspension test. ⁎ Corresponding author. Tel.: +55 48 3721 5043; fax: +55 48 3721 9672. guanidine compound that plays a pivotal role in brain energy homeostasis E-mail addresses: [email protected], [email protected] (A.L.S. Rodrigues). (Andres et al., 2008)andpresentasignificant role in the pathophysiology 0278-5846 © 2013 Elsevier Inc. Open access under the Elsevier OA license. http://dx.doi.org/10.1016/j.pnpbp.2013.01.014 40 M.P. Cunha et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 44 (2013) 39–50 and treatment of depression. Thus, an inverse correlation between (Pfizer, Brazil). All drugs were dissolved in saline, except creatine, imipra- Hamilton Depression Rating Scale scores and white matter creatine mine, amitriptyline and reboxetine which were dissolved in distilled levels was shown (Dager et al., 2004). Furthermore, a single prolonged water. All drugs were administered by intraperitoneal (i.p.) route, except stress and forced swimming stress was reported to decrease creatine creatine, imipramine, amitriptyline and reboxetine which were adminis- concentrations in the rat prefrontal cortex (Herring et al., 2008; Kim tered by oral route (p.o.) by gavage and creatine and phenylephrine that et al., 2010; Knox et al., 2010). Noteworthy, creatine supplementation was administered by intracerebroventricular (i.c.v.) route. All drugs, has been proposed as a putative antidepressant in preclinical studies except those administered centrally, were administered in a constant vol- (Allen et al., 2010, 2012; Cunha et al., 2012) and clinical trials (Kondo ume of 10 ml/kg body weight. et al., 2011,2012;Roitman et al., 2007). However, the mechanisms underlying its antidepressant effects are not well established. Our 2.3. I.c.v. administration group recently demonstrated that an acute administration of creatine to mice elicits an antidepressant-like effect in the tail suspension test I.c.v. administration was performed using a microsyringe (25 μl, Ham- (TST) dependent on the dopaminergic activation (Cunha et al., 2012). ilton) connected to a 26-gauge stainless-steel needle that was inserted Furthermore, considering that noradrenaline terminals regulate extra- perpendicularly 2 mm deep through the skull according to the procedure cellular dopamine concentrations in the prefrontal cortex (Yamamoto originally described by Laursen and Belknap (1986),whichwasmodified and Novotney, 1998), we hypothesized that the antidepressant-like from the method of Haley and McCormick (1957).Briefly, the animals effect of creatine also involves noradrenergic system modulation. were anesthetized with ether and then gently restrained by hand for The noradrenergic system is involved in the regulation of many phys- i.c.v. injections. The sterilization of the injection site was carried out iological and psychological processes, including the modulation of mood. using gauze embedded in 70% ethanol. Under light anesthesia (i.e. just α The -adrenergic receptors modulate noradrenaline release (Rump and that necessary for loss of the postural reflex), the needle was inserted uni- Majewski, 1987), as well as dopamine release (Verheij and Cools, 2009) laterally 1 mm to the midline point equidistant from each eye, at an equal and are therefore potential targets for antidepressant drug development. distance between the eyes and the ears and perpendicular to the plane of Of note, a number of antidepressant drugs have been found to increase the skull. A volume of 5 μl of sterile saline containing the drugs was α 1-adrenoceptors function (Holsboer and Barden, 1996), since they are injected directly into the lateral ventricle, at the following coordinates α able to increase the density of 1-adrenoceptors in the hippocampus from bregma taken from the atlas of Franklin and Paxinos (1997): and cerebral cortex of mice and rats (Deupree et al., 2007; Rehavi et anterioposterior (AP)=−0.1 mm; mediolateral (ML)=1 mm; and dor- α fi al., 1980)andthe 1-adrenoceptor agonist af nity in the cerebral soventral (DV)=−3 mm. Mice exhibited normal behavior within 1 min ń cortex (Klimek et al., 1991; Nowak and Przegali ski, 1988). Moreover, after injection. After completion of the experiments, all animals were α the 1-adrenoceptor blockade in the central nervous system induces decapitated
Load more

Recommended publications
  • Neurotransmitter Resource Guide
    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
    [Show full text]
  • THE BIOSYNTHESIS of SOME PHENOLIC ALKALOIDS a Thesis Submitted by GEOFFREY MELVILLE THOMAS for the Degree of DOCTOR of PHILOSOPH
    /1 THE BIOSYNTHESIS OF SOME PHENOLIC ALKALOIDS a thesis submitted by GEOFFREY MELVILLE THOMAS for the degree of DOCTOR OF PHILOSOPHY of THE UNIVERSITY OF LONDON Imperial College, June 1963. London, S. W.7. ABSTRACT A brief review of the biosynthesis of alkaloids, other than those of the Amaryllidaceae and morphine groups, is given. The biosynthesis of these two groups is discussed more fully with particular reference to the evidence for the Barton and Cohen concept of phenol oxidation as a biogenetic mechanism. The incorporation of labelled phenolic precursors, derivatives of norbelladine, has been shown and by means of multiple labelled experiments incorporation as a whole, without degradation, has been proved. Other experiments described have thrown light on the earlier stages of biogenesis. The norlaudanosine derivative, (±) reticuline, has been shown to be incorporated into morphine, and an in vitro synthesis of thebaine from (±) reticuline using a radiochemical dilution method is de-scribed. I am deeply grateful to Professor D. H. R. Barton and Dr. G. W. Kirby for the privilege and pleasure of working under their supervision and for their great help in matters chemical and non-chemical. To the Salters Company I would like to express my sincere thanks for the award of a scholarship and for their interest during the tenure of it. My thanks are also due to Dr. D. W. Turner for advice on counting techniques, Mr. D. Aldrich and his staff for valuable technical assistance, Miss J. Cuckney for microanalyses, Mr. R.H. Young who grew the daffodils and poppies and to my many friends and co-workers at Imperial College.
    [Show full text]
  • Mrx CLINICAL ALERT
    MRx AUGUST 2018 CLINICAL ALERT YOUR MONTHLY SOURCE FOR DRUG INFORMATION HIGHLIGHTS HOT TOPIC: potential to placebo in non-dependent FIRST DRUG COMPRISED adult recreational drug users. EDITORIAL OF ACTIVE MARIJUANA DERIVATIVE APPROVED Cannabidiol oral solution was studied STAFF in 3 randomized, double-blind, placebo- Under Priority review, the United States controlled clinical trials including 516 (US) Food and Drug Administration (FDA) patients with either LGS or Dravet EDITOR IN CHIEF approved cannabidiol oral solution syndrome. Cannabidiol taken with ® Maryam Tabatabai (Epidiolex ) for the treatment of the patient’s current anticonvulsant PharmD seizures associated with Lennox-Gastaut regimen was shown to be effective syndrome (LGS) or Dravet syndrome in in reducing the frequency of seizures patients ≥ 2 years of age. It is the only when compared with placebo. Over EXECUTIVE EDITOR drug approved to treat Dravet syndrome the 12-week treatment period, the Carole Kerzic and the FDA designated it as an Orphan reduction in median number of LGS RPh drug and Rare pediatric disease drug seizures ranged from 37% to 44% with to treat both serious, difficult-to-treat CBD and 17% to 22% with placebo. DEPUTY EDITORS childhood seizure disorders. Dravet For Dravet syndrome, seizure reductions Stephanie Christofferson syndrome is diagnosed in approximately were 39% and 13% with CBD and PharmD 1 in 15,700 individuals in the US and placebo, respectively. Common side is characterized by frequent prolonged effects (≥ 10%) reported with CBD Jessica Czechowski seizures and developmental delays. LGS were increased liver transaminases PharmD involves frequent drop seizures and (particularly with concurrent use of impaired intellectual development.
    [Show full text]
  • Tyrosine Hydroxylase Inhibition in Substantia Nigra Decreases Movement Frequency
    Molecular Neurobiology (2019) 56:2728–2740 https://doi.org/10.1007/s12035-018-1256-9 Tyrosine Hydroxylase Inhibition in Substantia Nigra Decreases Movement Frequency Michael F. Salvatore1 & Tamara R. McInnis1 & Mark A. Cantu1 & Deana M. Apple2 & Brandon S. Pruett3,4 Received: 23 May 2018 /Accepted: 17 July 2018 /Published online: 28 July 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Reduced movement frequency or physical activity (bradykinesia) occurs with high prevalence in the elderly. However, loss of striatal tyrosine hydroxylase (TH) in aging humans, non-human primates, or rodents does not reach the ~ 80% loss threshold associated with bradykinesia onset in Parkinson’s disease. Moderate striatal dopamine (DA) loss, either following TH inhibition or decreased TH expression, may not affect movement frequency. In contrast, moderate DA or TH loss in the substantia nigra (SN), as occurs in aging, is of similar magnitude (~ 40%) to nigral TH loss at bradykinesia onset in Parkinson’sdisease.Inaged rats, increased TH expression and DA in SN alone increases movement frequency, suggesting aging-related TH and DA loss in the SN contributes to aging-related bradykinesia or decreased physical activity. To test this hypothesis, the SN was targeted with bilateral guide cannula in young (6 months old) rats, in a within-subjects design, to evaluate the impact of nigral TH inhibition on movement frequency and speed. The TH inhibitor, α-methyl-p-tyrosine (AMPT) reduced nigral DA (~ 40%) 45–150 min following infusion, without affecting DA in striatum, nucleus accumbens, or adjacent ventral tegmental area. Locomotor activity in the open-field was recorded up to 3 h following nigral saline or AMPT infusion in each test subject.
    [Show full text]
  • Today's Topic
    May 7, 2021 Vol. 1, No. 8 Palliative Care Pharmacy Team: TODAY’S TOPIC: Antidepressant Adverse Drug Reactions: Focus on QT Prolongation Clinical Pharmacy Specialist: Background: Antidepressants have been used for many years to treat mental health conditions such as Maria Felton Lowry, depression and anxiety (not an all-inclusive list). Their mechanisms are somewhat unique to the PharmD, BCPS, BCGP class of antidepressant, for instance, tricyclic antidepressants are thought to delay the inward Assistant Professor sodium current into cardiomyocytes, slowing cardiac depolarization. In contrast, SSRIs directly block potassium channels and disrupt hERG protein expression, both reducing potassium ion flow. University of Pittsburgh Palliative care clinicians use these medications commonly in clinical practice for symptom School of Pharmacy, management and should be aware of their potential side effects. Department of Pharmacy and Therapeutics Importance: Palliative Antidepressants can cause QTc prolongation. As stated in previous weeks, clinically significant QTc Care Clinical Pharmacy prolongation is an absolute QTc > 500 msec, QTc > 25% from baseline, or change of QTc > 60 Specialist msec.1 The degree of QTc prolongation is a modest predictor of the risk of Torsades de Pointes UPMC Palliative and (TdP) and sudden cardiac death.2 Still, it is important for palliative care clinicians be aware of this Supportive Institute risk of commonly prescribed medications in our practice. Cell: 412-627-8473 Known QTc prolongation risk factors: Office: 412-864-2899
    [Show full text]
  • Assessment Report
    19 September 2013 EMA/737723/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report ABILIFY MAINTENA International non-proprietary name: ARIPIPRAZOLE Procedure No. EMEA/H/C/002755/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Table of contents 1.1. Submission of the dossier .................................................................................... 6 1.2. Manufacturers ................................................................................................... 6 1.3. Steps taken for the assessment of the product ....................................................... 7 2. Scientific discussion ................................................................................ 7 2.1. Introduction ...................................................................................................... 7 2.2. Quality aspects .................................................................................................. 9 2.2.1. Introduction ................................................................................................... 9 2.2.2. Active Substance ..........................................................................................
    [Show full text]
  • Binding Energies of Tyrosine Kinase Inhibitors: Error Assessment of Computational Methods for Imatinib and Nilotinib Binding Clifford Fong
    Binding Energies of Tyrosine Kinase Inhibitors: error assessment of computational methods for imatinib and nilotinib binding Clifford Fong To cite this version: Clifford Fong. Binding Energies of Tyrosine Kinase Inhibitors: error assessment of computational methods for imatinib and nilotinib binding. Computational Biology and Chemistry, Elsevier, 2015, 58, pp.40-54. 10.1016/j.compbiolchem.2015.05.002. hal-01344991 HAL Id: hal-01344991 https://hal.archives-ouvertes.fr/hal-01344991 Submitted on 13 Jul 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Computational Biology and Chemistry, 18 May 2015, doi:10.1016/j.compbiolchem.2015.05.002 Computational Biology and Chemistry 58 (2015) 40–54 Binding Energies of Tyrosine Kinase Inhibitors: error assessment of computational methods for imatinib and nilotinib binding Clifford W. Fong* Eigenenergy, Adelaide, South Australia, Australia * Author to whom correspondence should be addressed; E-Mail: [email protected] The binding energies of imatinib and nilotinib to tyrosine kinase have been determined by quantum mechanical (QM) computations, and compared with literature binding energy studies using molecular mechanics (MM). The potential errors in the computational methods include these critical factors: Errors in X-ray structures such as structural distortions and steric clashes give unrealistically high van der Waals energies, and erroneous binding energies.
    [Show full text]
  • Wednesday, June 12, 2019 4:00Pm
    Wednesday, June 12, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – June 12, 2019 DATE: June 5, 2019 Note: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the June meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Use of Angiotensin Converting Enzyme Inhibitor (ACEI)/ Angiotensin Receptor Blocker (ARB) Therapy in Patients with Diabetes and Hypertension (HTN) Mailing Update – Appendix B Action Item – Vote to Prior Authorize Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase) – Appendix C Action Item – Vote to Prior Authorize Plenvu® [Polyethylene Glycol (PEG)-3350/Sodium Ascorbate/Sodium Sulfate/Ascorbic Acid/Sodium Chloride/Potassium Chloride] – Appendix D Action Item – Vote to Prior Authorize Consensi® (Amlodipine/Celecoxib) and Kapspargo™ Sprinkle [Metoprolol Succinate Extended-Release (ER)] – Appendix E Action Item – Vote to Update the Prior Authorization Criteria For H.P. Acthar® Gel (Repository Corticotropin Injection) – Appendix F Action Item – Vote to Prior Authorize Fulphila® (Pegfilgrastim-jmdb), Nivestym™ (Filgrastim-aafi),
    [Show full text]
  • Psychopharmacology '! by Springer-Verlag 1978
    m : t Aoq Psychopharmacolos5y9, tl 3- 116(1978) Psychopharmacology _'! by Springer-Verlag 1978 Effects of LSD and BOL on the Catecholamine Synthesis and Turnover in Various Brain Regions Sven-Ake Persson Departmentof Pharmacology,Universityof Ume_, S-90I87 Ume_, Sweden Abstract. In the rat, lysergic acid diethylamide (LSD) cerebral dopamine (DA) levels (Diaz et al., 1968). 0.5 mg/kg and 2-bromo lysergic acid diethylamide However, increased cerebral DA levels after LSD have - (BOL) 0.5 mg/kg increased the rate of the striatal in also been reported (Smith et al., (1975), Relatively few vivo tyrosine hydroxylation as measured by the DOPA studies on the cerebral catecholamine turnover have accumulation after decarboxylase inhibition. Neither been reported. High doses of LSD increased the LSD nor BOL significantly changed the DOPA accu- disappearance of NA in the rat brain after treatment mulation in the olfactory tubercle, a dopamine-rich with a-methyl-p-tyrosine methylester (a-MT) (And6n part of the limbic system. LSD but not BOL increased et ai., 1968). LSD did not affect the disappearance of the DOPA accumulation in the cerebral cortex and in DA. Da Prada et al. (1975) found that LSD decreased the brain stem. LSD and BOL appeared not to alter the the disappearance of DA in the rat teldiencephalon rate ofa-MT-induced disappearance of DA or of NA in after _t-MT and that LSD also decreased the homova- the whole brain, nor did they change the rate of the a- nillic acid (HVA) level in the striatum and in the eyes, MT-induced disappearance of DA in the striatum.
    [Show full text]
  • Indications for Use Form
    DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service ____________________________________________________________________________________________________________________________ Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002 W.H.P.M., INC. February 26, 2015 JOHN WAN 5358 IRWINDALE AVENUE IRWINDALE CA 91706 Re: K150162 Trade/Device Name: First Sign® Drug Of Abuse Cup Test First Sign® Drug Of Abuse Dip Card Test Regulation Number: 21 CFR 862.3610 Regulation Name: Methamphetamine test system Regulatory Class: II Product Code: LAF, JXM, DJG Dated: January 19, 2015 Received: January 26, 2015 Dear Mr. John Wan: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls.
    [Show full text]
  • Visible Light Photoredox Catalysis with Transition Metal Complexes: Applications in Organic Synthesis Christopher K
    Review pubs.acs.org/CR Visible Light Photoredox Catalysis with Transition Metal Complexes: Applications in Organic Synthesis Christopher K. Prier, Danica A. Rankic, and David W. C. MacMillan* Merck Center for Catalysis at Princeton University, Princeton, New Jersey 08544, United States References 5360 1. INTRODUCTION CONTENTS A fundamental aim in the field of catalysis is the development 1. Introduction 5322 of new modes of small molecule activation. One approach 2+ toward the catalytic activation of organic molecules that has 2. Photochemistry of Ru(bpy)3 5323 3. Net Reductive Reactions 5324 received much attention recently is visible light photoredox 3.1. Reduction of Electron-Poor Olefins 5324 catalysis. In a general sense, this approach relies on the ability of 3.2. Reductive Dehalogenation 5326 metal complexes and organic dyes to engage in single-electron- 3.3. Reductive Cleavage of Sulfonium and transfer (SET) processes with organic substrates upon Sulfonyl Groups 5328 photoexcitation with visible light. 3.4. Nitrogen Functional Group Reductions 5329 Many of the most commonly employed visible light 3.5. Radical Cyclizations 5330 photocatalysts are polypyridyl complexes of ruthenium and iridium, and are typified by the complex tris(2,2′-bipyridine) 3.6. Reductive Epoxide and Aziridine Opening 5331 2+ 3.7. Reduction-Labile Protecting Groups 5331 ruthenium(II), or Ru(bpy)3 (Figure 1). These complexes 4. Net Oxidative Reactions 5332 4.1. Functional Group Oxidations 5332 4.2. Oxidative Removal of the PMB Group 5334 4.3. Oxidative Biaryl Coupling 5335 4.4. Oxidative Generation of Iminium Ions 5335 4.5. Azomethine Ylide [3 + 2] Cycloadditions 5338 4.6.
    [Show full text]
  • Induced Catecholamine Depletion in Patients with Seasonal Affective Disorder in Summer Remission Raymond W
    Effects of Alpha-Methyl-Para-Tyrosine- Induced Catecholamine Depletion in Patients with Seasonal Affective Disorder in Summer Remission Raymond W. Lam, M.D., Edwin M. Tam, M.D.C.M., Arvinder Grewal, B.A., and Lakshmi N. Yatham, M.B.B.S. Noradrenergic and dopaminergic mechanisms have been the control diphenhydramine session. The AMPT session proposed for the pathophysiology of seasonal affective resulted in higher depression ratings with all nine patients disorder (SAD). We investigated the effects of having significant clinical relapse, compared with two catecholamine depletion using ␣-methyl-para-tyrosine patients during the diphenhydramine session. All patients (AMPT), an inhibitor of tyrosine hydroxylase, in patients returned to baseline scores after drug discontinuation. with SAD in natural summer remission. Nine drug-free Catecholamine depletion results in significant clinical patients with SAD by DSM-IV criteria, in summer relapse in patients with SAD in the untreated, summer- remission for at least eight weeks, completed a double-blind, remitted state. AMPT-induced depressive relapse may be a crossover study. Behavioral ratings and serum HVA and trait marker for SAD, and/or brain catecholamines may MHPG levels were obtained for 3-day sessions during play a direct role in the pathogenesis of SAD. which patients took AMPT or an active control drug, [Neuropsychopharmacology 25:S97–S101, 2001] diphenhydramine.The active AMPT session significantly © 2001 American College of Neuropsychopharmacology. reduced serum levels of HVA and MHPG compared with Published by Elsevier Science Inc. KEY WORDS: Seasonal affective disorder; Alpha-methyl- pattern, with full remission of symptoms (or a switch para-tyrosine; Catecholamines; Dopamine; Noradrenaline; into hypomania/mania) during spring/summer.
    [Show full text]